JAGSONPAL PHARMACEUTICALS
JAGSNPHARM · NSE
221.94
-9.02 (-3.91%)
as of 29 Oct 2026 close
Open
219.52
High
231.81
Low
211.00
Prev close
230.96
52w high
264.50
30 Jun 2026
52w low
155.00
22 Jan 2026
VWAP
220.28
Delivery %
26.1%
of volume
Volume 2.49 L · turnover ₹5.49 Cr · NSE bhavcopy (official close), adjusted for splits/bonuses · history since 04 Jan 2010
- ISIN
- INE048B01035
- Series
- EQ
- Listed on NSE
- 01 Mar 2000
- Face value
- ₹2
- F&O
- No
Source: NSE equity master · as of 30 Oct 2026
Daily · NSE EOD
Quarterly results · Standalone · latest 30 Sept 2026
filed 28 Oct 2026, 08:21 pm IST| ₹ crore | Sept 26* |
|---|---|
| Revenue | 81 |
| Other income | 2 |
| Total expenses | 67 |
| Operating margin | 20.3% |
| Finance costs | 0 |
| Depreciation | 2 |
| Profit before tax | 17 |
| Tax | 4 |
| Net profit | 13 |
| Net margin | 15.5% |
| EPS (₹) | 1.91 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison